Skip to Content

Qternmet XR Approval History

FDA Approved: Yes (First approved May 2, 2019)
Brand name: Qternmet XR
Generic name: dapagliflozin, metformin hydrochloride and saxagliptin
Dosage form: Extended-Release Tablets
Company: AstraZeneca
Treatment for: Diabetes, Type 2

Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Development History and FDA Approval Process for Qternmet XR

DateArticle
May  3, 2019Approval FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide